header-logo
Staff Collaborate Conference Room
James Verbsky, MD, PhD
James Verbsky, MD, PhD

James Verbsky, MD, PhD

Professor, Pediatrics (Rheumatology) and Microbiology & Immunology; Medical Director, Clinical Immunology Research Laboratory; Medical Director, Clinical and Translational Research

Locations

  • Children's Wisconsin
    Children's Corporate Center
    Suite C465

Contact Information

General Interests

Primary Immune Deficiency, Immune Dysregulation Syndromes

Education

PhD, Immunology, Washington University, 2000
MD, Washington University, 2000
Fellowship, Pediatric Rheumatology, Washington University

Research Interests

My research interests focus on immune regulation, and my research program is based on the premise of taking genetically defined immune deficiencies from humans and modeling these diseases in the laboratory. Since I see patients with immune deficiencies and inflammatory disorders, the first step in this program is to define the immune deficiency in these patients. Using genetic technologies, such as copy number variation analysis, targeted gene sequencing, and next generation genetic sequencing, we have been successful at defining several primary immune deficiencies, and have used these findings to model these diseases in the laboratory to help us understand immunity and immune regulation.

Publications

  • Effect of an Electronic Pill Bottle on Hydroxychloroquine Adherence in Pediatric Lupus: Results of a Novel Direct-to-Family Pilot Trial

    (Randell RL, Schanberg LE, Beard C, Phillips T, Hornik CP, Cohen-Wolkowiez M, Balevic SJ, Rubinstein T, Vasquez N, Wahezi D, Tanner T, Peskin M, Rothschild E, Perfetto J, Guzman L, Buckley L, Patrick A, Datyner E, Blackmon B, Graham T, Henderson L, Lo M, Lee P, Sundel R, Meidan E, Halyabar O, Nigrovic P, Son MB, Hausmann J, McBrearty K, Cohen E, Chang M, Chang J, Dedeoglu F, Cidon M, Reyhan I, Haro S, Shaham B, Cancino A, Brown D, Marzan K, Weiss P, Lerman M, Moreno J, Canna S, Devine R, Torok K, Rosenkranz M, Patel J, Stapp H, Kienzle B, Newhall L, Klein-Gitelman M, Miller M, Hiskey M, Nolan B, Amoruso M, De Ranieri D, Patel P, Lytch A, Cooper A, Holland MJ, Favier L, Fox E, Ibarra M, Hoffart C, Jones J, Harris J, Srinivasalu H, Connor R, Sule S, Ronis T, Ogbonnaya-Whittesley S, Dizon B, Sherman M, Dunnock K, Angeles-Han S, Vega-Fernandez P, Quinlan-Waters M, Brunner H, Schulert G, Grom A, Henrickson M, Huggins J, Lovell D, Ting T, Ogbu E, Zeft A, Robinson A, Brooks E, Panupattanapong S, Parsons A, Edelheit B, Lapin B, Twachtman-Bassett J, Tory H, Fennell J, Jiang Y, Rodgers L, Swaffar C.) Acr Open Rheumatology. January 2025;7(1) SCOPUS ID: 2-s2.0-85216072708 01/01/2025

  • Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry Study.

    (Soulsby WD, Olveda R, He J, Berbert L, Weller E, Barbour KE, Greenlund KJ, Schanberg LE, von Scheven E, Hersh A, Son MBF, Chang J, Knight A, CARRA Registry Investigators.) Arthritis Care Res (Hoboken). 2025 Jan;77(1):38-49 PMID: 39344152 PMCID: PMC11684980 SCOPUS ID: 2-s2.0-85206931820 09/30/2024

  • Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses.

    (Saper VE, Tian L, Verstegen RHJ, Conrad CK, Cidon M, Hopper RK, Kuo CS, Osoegawa K, Baszis K, Bingham CA, Ferguson I, Hahn T, Horne A, Isupova EA, Jones JT, Kasapcopur Ö, Klein-Gitelman MS, Kostik MM, Ozen S, Phadke O, Prahalad S, Randell RL, Sener S, Stingl C, Abdul-Aziz R, Akoghlanian S, Al Julandani D, Alvarez MB, Bader-Meunier B, Balay-Dustrude EE, Balboni I, Baxter SK, Berard RA, Bhattad S, Bolaria R, Boneparth A, Cassidy EA, Co DO, Collins KP, Dancey P, Dickinson AM, Edelheit BS, Espada G, Flanagan ER, Imundo LF, Jindal AK, Kim HA, Klaus G, Lake C, Lapin WB, Lawson EF, Marmor I, Mombourquette J, Ogunjimi B, Olveda R, Ombrello MJ, Onel K, Poholek C, Ramanan AV, Ravelli A, Reinhardt A, Robinson AD, Rouster-Stevens K, Saad N, Schneider R, Selmanovic V, Sefic Pasic I, Shenoi S, Shilo NR, Soep JB, Sura A, Taber SF, Tesher M, Tibaldi J, Torok KS, Tsin CM, Vasquez-Canizares N, Villacis Nunez DS, Way EE, Whitehead B, Zemel LS, Sharma S, Fernández-Viña MA, Mellins ED, CARRA Registry Investigators.) J Allergy Clin Immunol Pract. 2024 Nov;12(11):2996-3013.e7 PMID: 39002722 PMCID: PMC11560592 SCOPUS ID: 2-s2.0-85201511504 07/14/2024

  • Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research.

    (Chang MH, Barbar-Smiley F, Akoghlanian S, Drew J, Angeles-Han ST, Quinlan-Waters M, Bohnsack JF, Cooper AM, Edelheit B, Twachtman-Bassett J, Lerman MA, Nanda K, Rabinovich CE, Lo MS, CARRA Uveitis Workgroup and the CARRA Registry Investigators.) Pediatr Rheumatol Online J. 2024 Oct 07;22(1):88 PMID: 39375683 PMCID: PMC11457454 SCOPUS ID: 2-s2.0-85205784510 10/08/2024

  • Maintenance of X chromosome inactivation after T cell activation requires NF-κB signaling.

    (Forsyth KS, Toothacre NE, Jiwrajka N, Driscoll AM, Shallberg LA, Cunningham-Rundles C, Barmettler S, Farmer J, Verbsky J, Routes J, Beiting DP, Romberg N, May MJ, Anguera MC.) Sci Immunol. 2024 Oct 04;9(100):eado0398 PMID: 39365876 PMCID: PMC12088372 SCOPUS ID: 2-s2.0-85205806529 10/04/2024

  • Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.

    (Mannion ML, Amin S, Balevic S, Chang ML, Correll CK, Kearsley-Fleet L, Hyrich KL, Beukelman T, Childhood Arthritis and Rheumatology Research Alliance Registry Investigators and the UK Juvenile Idiopathic Arthritis Biologics Register Investigators.) Arthritis Care Res (Hoboken). 2024 Aug;76(8):1090-1098 PMID: 38556945 PMCID: PMC11288784 SCOPUS ID: 2-s2.0-85192273021 04/01/2024

  • COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report.

    (McDonnell J, Cousins K, Younger MEM, Lane A, Abolhassani H, Abraham RS, Al-Tamemi S, Aldave-Becerra JC, Al-Faris EH, Alfaro-Murillo A, AlKhater SA, Alsaati N, Doss AMA, Anderson M, Angarola E, Ariue B, Arnold DE, Assa'ad AH, Aytekin C, Bank M, Bergerson JRE, Bleesing J, Boesing J, Bouso C, Brodszki N, Cabanillas D, Cady C, Callahan MA, Caorsi R, Carbone J, Carrabba M, Castagnoli R, Catanzaro JR, Chan S, Chandra S, Chapdelaine H, Chavoshzadeh Z, Chong HJ, Connors L, Consonni F, Correa-Jimenez O, Cunningham-Rundles C, D'Astous-Gauthier K, Delmonte OM, Demirdag YY, Deshpande DR, Diaz-Cabrera NM, Dimitriades VR, El-Owaidy R, ElGhazali G, Al-Hammadi S, Fabio G, Faure AS, Feng J, Fernandez JM, Fill L, Franco GR, Frenck RW, Fuleihan RL, Giardino G, Galant-Swafford J, Gambineri E, Garabedian EK, Geerlinks AV, Goudouris E, Grecco O, Pan-Hammarström Q, Khani HHK, Hammarström L, Hartog NL, Heimall J, Hernandez-Molina G, Horner CC, Hostoffer RW, Hristova N, Hsiao KC, Ivankovich-Escoto G, Jaber F, Jalil M, Jamee M, Jean T, Jeong S, Jhaveri D, Jordan MB, Joshi AY, Kalkat A, Kanarek HJ, Kellner ES, Khojah A, Khoury R, Kokron CM, Kumar A, Lecerf K, Lehman HK, Leiding JW, Lesmana H, Lim XR, Lopes JP, López AL, Tarquini L, Lundgren IS, Magnusson J, Marinho AKBB, Marseglia GL, Martone GM, Mechtler AG, Mendonca L, Milner JD, Mustillo PJ, Naderi AG, Naviglio S, Nell J, Niebur HB, Notarangelo L, Oleastro M, Ortega-López MC, Patel NR, Petrovic G, Pignata C, Porras O, Prince BT, Puck JM, Qamar N, Rabusin M, Raje N, Regairaz L, Risma KA, Ristagno EH, Routes J, Roxo-Junior P, Salemi N, Scalchunes C, Schuval SJ, Seneviratne SL, Shankar A, Sherkat R, Shin JJ, Siddiqi A, Signa S, Sobh A, Lima FMS, Stenehjem KK, Tam JS, Tang M, Barros MT, Verbsky J, Vergadi E, Voelker DH, Volpi S, Wall LA, Wang C, Williams KW, Wu EY, Wu SS, Zhou JJ, Cook A, Sullivan KE, Marsh R.) J Clin Immunol. 2024 Apr 05;44(4):86 PMID: 38578389 PMCID: PMC10997719 SCOPUS ID: 2-s2.0-85190084914 04/05/2024

  • NF-κB Signaling is Required for X-Chromosome Inactivation Maintenance Following T cell Activation.

    (Forsyth KS, Toothacre NE, Jiwrajka N, Driscoll AM, Shallberg LA, Cunningham-Rundles C, Barmettler S, Farmer J, Verbsky J, Routes J, Beiting DP, Romberg N, May MJ, Anguera MC.) bioRxiv. 2024 Feb 12 PMID: 38405871 PMCID: PMC10888971 02/26/2024

  • Impaired B-cell function in ERCC2 deficiency.

    (Rossmanith R, Sauerwein K, Geier CB, Leiss-Piller A, Stemberger RF, Sharapova S, Gruber RW, Bergler H, Verbsky JW, Csomos K, Walter JE, Wolf HM.) Front Immunol. 2024;15:1423141 PMID: 39055713 PMCID: PMC11269123 SCOPUS ID: 2-s2.0-85199339873 07/26/2024

  • Corrigendum: Patients with juvenile idiopathic arthritis have decreased clonal diversity in the CD8+ T cell repertoire response to influenza vaccination.

    (Sabbagh SE, Haribhai D, Gershan JA, Verbsky J, Nocton J, Yassai M, Naumova EN, Hammelev E, Dasgupta M, Yan K, Gorski J, Williams CB.) Front Immunol. 2024;15:1446946 PMID: 38962010 PMCID: PMC11220386 SCOPUS ID: 2-s2.0-85197728513 07/04/2024

  • Patients with juvenile idiopathic arthritis have decreased clonal diversity in the CD8+ T cell repertoire response to influenza vaccination.

    (Sabbagh SE, Haribhai D, Gershan JA, Verbsky J, Nocton J, Yassai M, Naumova EN, Hammelev E, Dasgupta M, Yan K, Gorski J, Williams CB.) Front Immunol. 2024;15:1306490 PMID: 38873594 PMCID: PMC11169902 SCOPUS ID: 2-s2.0-85195642328 06/14/2024

  • Common Variable Immunodeficiency

    (Remiker A, Bolling K, Verbsky J.) Medical Clinics of North America. January 2024;108(1):107-121 SCOPUS ID: 2-s2.0-85165659522 01/01/2024

Publications of James Verbsky MD, PhD from the Faculty Collaboration Database

© 2025 Medical College of Wisconsin.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The Medical College of Wisconsin (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. MCW maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

MCW's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.